查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1874529

全球眼科药品市场

Ophthalmic Pharmaceutical Drugs
出版日期: | 出版商: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 英文 272 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计到2030年，全球眼科药品市场规模将达到1,025亿美元。

2024年全球眼科药品市场规模估计为830亿美元，预计到2030年将达到1025亿美元，在分析期（2024-2030年）内复合年增长率（CAGR）为3.6%。本报告分析的细分市场之一—抗VEGF药物，预计将以4.4%的复合年增长率成长，并在分析期结束时达到343亿美元。抗青光眼药物细分市场预计在分析期间将以2.7%的复合年增长率成长。

美国市场规模估计为221亿美元，而中国市场预计将以6.3%的复合年增长率成长。

据估计，2024年美国眼科药品市场规模将达221亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到214亿美元，在2024年至2030年的分析期间内，复合年增长率（CAGR）为6.3%。其他值得关注的区域市场分析包括日本和加拿大，预计在分析期间内，两国的复合年增长率分别为0.7%和4.3%。在欧洲，德国的复合年增长率预计约为1.6%。

全球眼科药品市场－主要市场趋势与驱动因素概述

什么是眼科药物？它们为什么重要？

眼科药物是专门用于治疗各种眼部疾病和病症的药物，包括青光眼、干眼症、感染疾病和发炎性疾病。这些药物设计用于直接给药于眼部，从而实现标靶治疗，最大限度地减少全身暴露，进而降低副作用。眼科药物包括抗生素、抗真菌药物和抗发炎药，以及用于治疗慢性疾病（例如老龄化黄斑部病变(AMD) 和糖尿病视网膜病变）的药物。随着全球眼科疾病率的不断上升，这些药物在保护视力、提高眼科疾病患者的生活品质方面发挥着至关重要的作用。

医学研究的进展对眼科药物领域有何影响？

医学研究的进步显着推动了新型高效眼科药物的研发。近年来，我们对主要眼科疾病生理机制的理解不断加深，促使人们研发出针对特定分子路径、标靶治疗这些疾病的创新药物。例如，抗血管内皮生长因子（VEGF）疗法透过抑制视网膜异常血管的生长，彻底改变了老龄化黄斑部病变（AMD）和糖尿病黄斑部水肿等疾病的治疗。此外，缓释性植入和奈米技术等药物传递技术的进步，透过促进药物吸收和延长作用时间，提高了治疗效果，这对于需要长期管理的慢性疾病尤其重要。

哪些趋势正在推动眼科製药产业的发展？

推动眼科製药产业发展的几个关键趋势是其中之一。全球人口老化是主要因素，老年人罹患多种眼科疾病的风险较高，包括青光眼和老龄化黄斑部病变。这种人口结构变化增加了对眼科治疗的需求，并推动了市场成长。此外，人们越来越偏好微创治疗，这促进了先进药物输送系统的发展，为传统手术提供了替代方案。随着全球糖尿病盛行率的上升，糖尿病视网膜病变的发生率也在增加，进一步提高了对有效治疗方法的需求。此外，人们对眼科疾病的认识不断提高，诊断技术的进步使得眼科疾病的早期发现和治疗成为可能，这也进一步推动了对眼科製药的需求。

哪些因素正在推动眼科药品市场的成长？

眼科药品市场的成长受多种因素驱动，包括药物研发和给药系统技术的进步，这些进步提高了治疗效果和患者依从性。全球老年人口的成长（老年人易患慢性眼科疾病）显着推动了眼科药品需求的成长。此外，糖尿病等慢性疾病在全球范围内的日益增多（这些疾病常伴随严重的眼部併发症）也促进了市场成长。消费者行为的改变促使他们倾向于选择更先进、创伤更小、恢復更快、副作用更少的治疗方法，意识提升，在市场扩张中发挥关键作用，确保了对这些重要药物的持续需求。

部分：

药物分类（抗 VEGF 药物、抗青光眼药物、抗发炎药物、抗过敏药物、其他药物分类）、类型（处方药、非处方药）

受访公司范例

  • Allergan PLC
  • Bayer AG
  • F. Hoffmann-La Roche AG
  • Johnson and Johnson Vision Care Inc
  • Kyowa Kirin Co., Ltd
  • Novartis International AG
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Santen Pharmaceuticals Co., Ltd.
  • Shire PLC

人工智慧集成

我们正在利用检验的专家内容和人工智慧工具，改变您分析市场和竞争情报的方式。

Global Industry Analysts 没有依赖查询通用 LLM（大规模语言模型）或产业专用的SLM（小规模语言模型），而是建立了一个由世界各地领域专家精心策划的内容库，其中包括视频转录、博客、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

我们最新发布的报告纳入了关税对区域市场的影响，正如全球产业分析师预测的那样，关税将改变企业的竞争地位，而企业的竞争地位将取决于其总部所在地、製造地以及进出口（成品和OEM产品）。这种复杂多变的市场现实将透过微观和宏观市场动态影响竞争对手，包括销货成本增加、盈利下降以及供应链重组。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章 市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 亚太其他地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 竞赛

简介目录
Product Code: MCP-1490

Global Ophthalmic Pharmaceutical Drugs Market to Reach US$102.5 Billion by 2030

The global market for Ophthalmic Pharmaceutical Drugs estimated at US$83.0 Billion in the year 2024, is expected to reach US$102.5 Billion by 2030, growing at a CAGR of 3.6% over the analysis period 2024-2030. Anti-VEGF Agents, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$34.3 Billion by the end of the analysis period. Growth in the Anti-Glaucoma segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$22.1 Billion While China is Forecast to Grow at 6.3% CAGR

The Ophthalmic Pharmaceutical Drugs market in the U.S. is estimated at US$22.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$21.4 Billion by the year 2030 trailing a CAGR of 6.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.7% and 4.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Ophthalmic Pharmaceutical Drugs Market - Key Trends & Drivers Summarized

What Are Ophthalmic Pharmaceutical Drugs and Why Are They Important?

Ophthalmic pharmaceutical drugs are specialized medications used to treat various eye conditions and diseases such as glaucoma, dry eye syndrome, infections, and inflammatory disorders. These drugs are formulated to be administered directly into the eye, ensuring targeted therapy with minimal systemic exposure, which can lead to reduced side effects. The range of ophthalmic drugs includes antibiotics, antifungal, anti-inflammatory agents, and treatments for chronic conditions like age-related macular degeneration (AMD) and diabetic retinopathy. With the rising incidence of eye-related ailments globally, these drugs play a critical role in preserving vision and improving the quality of life for patients suffering from ocular diseases.

How Are Advances in Medical Research Shaping the Ophthalmic Drugs Sector?

Advancements in medical research have significantly influenced the development of new and more effective ophthalmic drugs. Recent breakthroughs in understanding the pathophysiology of major eye diseases have led to the innovation of drugs that target specific molecular pathways involved in these conditions. For example, anti-VEGF (Vascular Endothelial Growth Factor) therapy has revolutionized the treatment of diseases like AMD and diabetic macular edema by inhibiting the growth of abnormal blood vessels in the retina. Additionally, advancements in drug delivery technology, such as sustained release implants and nanotechnology-based systems, have improved the efficacy of treatments by enhancing drug absorption and prolonging the duration of action, which is particularly beneficial for chronic diseases that require long-term management.

What Trends Are Driving the Ophthalmic Pharmaceutical Drugs Industry?

Several key trends are driving the ophthalmic pharmaceutical drugs industry. An aging global population is a major factor, as older individuals are at a higher risk for developing many types of eye diseases, including glaucoma and AMD. This demographic shift is increasing the demand for ophthalmic treatments and driving growth in the market. Furthermore, there is an increasing preference for minimally invasive treatments, which has spurred the development of advanced drug delivery systems that offer alternatives to traditional surgeries. The rise in prevalence of diabetes worldwide has also escalated the incidence of diabetic retinopathy, prompting a greater need for effective therapeutic interventions. Additionally, increased awareness and improved diagnostic techniques are enabling earlier detection and treatment of eye conditions, further propelling the demand for ophthalmic drugs.

What Drives the Growth of the Ophthalmic Pharmaceutical Drugs Market?

The growth in the ophthalmic pharmaceutical drugs market is driven by several factors, including technological advancements in drug development and delivery systems that enhance treatment efficacy and patient compliance. The expanding geriatric population globally, which is more susceptible to chronic eye conditions, significantly contributes to the increasing demand for ophthalmic medications. Moreover, the global increase in chronic diseases such as diabetes, which are often associated with serious eye complications, also boosts the market growth. Consumer behavior is shifting towards preferring advanced, less invasive treatment options that offer quicker recovery and fewer side effects, which in turn drives the adoption of innovative ophthalmic drugs. Lastly, governmental and non-governmental efforts to raise awareness about eye health and improve accessibility to ophthalmic treatments play crucial roles in the market expansion, ensuring a sustained demand for these vital medications.

SCOPE OF STUDY:

The report analyzes the Ophthalmic Pharmaceutical Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy, Other Drug Classes); Type (Prescription Drugs, Over-the-Counter Drugs)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • Allergan PLC
  • Bayer AG
  • F. Hoffmann-La Roche AG
  • Johnson and Johnson Vision Care Inc
  • Kyowa Kirin Co., Ltd
  • Novartis International AG
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Santen Pharmaceuticals Co., Ltd.
  • Shire PLC

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
    • Global Economic Update
    • Ophthalmic Pharmaceutical Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advances in Drug Delivery Systems Propel Growth in Ophthalmic Pharmaceutical Drugs Market
    • Increasing Prevalence of Eye Disorders Expands Addressable Market Opportunity
    • Technological Innovations in Formulations Generate Demand for Advanced Ophthalmic Drugs
    • Growth in Geriatric Population Drives Adoption of Ophthalmic Pharmaceuticals
    • Rising Awareness of Eye Health Strengthens Business Case for Preventative Treatments
    • Adoption of Biologics and Biosimilars Spurs Growth in Ophthalmic Drug Market
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Ophthalmic Pharmaceutical Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Ophthalmic Pharmaceutical Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Anti-VEGF Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Anti-VEGF Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Anti-VEGF Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Anti-Glaucoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Anti-Glaucoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Anti-Glaucoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Anti-Inflammatory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Anti-Inflammatory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Anti-Inflammatory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Anti-Allergy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Anti-Allergy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Anti-Allergy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Prescription Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Prescription Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Prescription Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Over-the-Counter Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Over-the-Counter Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Over-the-Counter Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • JAPAN
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • CHINA
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • EUROPE
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Ophthalmic Pharmaceutical Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • FRANCE
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • GERMANY
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Ophthalmic Pharmaceutical Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • INDIA
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Ophthalmic Pharmaceutical Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Ophthalmic Pharmaceutical Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
  • AFRICA
    • Ophthalmic Pharmaceutical Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Ophthalmic Pharmaceutical Drugs by Drug Class - Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Drug Class - Percentage Breakdown of Value Sales for Anti-VEGF Agents, Anti-Glaucoma, Anti-Inflammatory, Anti-Allergy and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Ophthalmic Pharmaceutical Drugs by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Ophthalmic Pharmaceutical Drugs by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030

IV. COMPETITION